Safecor Health Initiates Class II Recall of Haloperidol Lactate Due to RFID Tag Mislabeling
Safecor Health, LLC has initiated a Class II recall for Haloperidol Lactate Injection due to incorrect RFID tag labels applied by the repackaging firm. This incident, impacting 800 vials distributed in Massachusetts, highlights critical vulnerabilities in third-party labeling processes, demanding immediate review by procurement and regulatory teams to mitigate supply chain risks and ensure patient safety.
FDA Findings: Critical Labeling Breach for Haloperidol Lactate Injection
Safecor Health, LLC, a repackaging firm based in Woburn, Massachusetts, has initiated a Class II recall for specific lots of Haloperidol Lactate Injection, 5 mg/mL. This voluntary, firm-initiated recall, designated D-0214-2026, stems from the application of incorrect RFID tag labels to the product. Specifically, the KITCHECK RFID tags attached to the 25 x 1 mL single-dose vials carried incorrect serial numbers: KITCHECK 8001-03A3,00000000,003A-2560 and 8001-03A3,00000000,003A-2D3B. The affected product, manufactured for Mylan Institutional LLC, includes Lot 25381993 and 25391516, both with an expiration date of 12/31/2026. A total of 800 1mL vials were distributed exclusively in Massachusetts. For procurement directors and supply chain VPs, this incident necessitates an immediate review of inventory and distribution records to identify any affected Haloperidol Lactate stock. The Class II classification indicates that the mislabeling could lead to temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, in a clinical setting, incorrect RFID tags can cause critical medication errors, disrupt automated dispensing systems, and compromise patient safety. Regulatory affairs heads must understand that such labeling discrepancies, even on ancillary tracking components like RFID tags, represent a significant lapse in quality control and compliance with Good Manufacturing Practices (GMP). This event underscores the imperative for stringent oversight of all third-party labeling and repackaging operations.
Repackaging Facility Profile: Safecor Health's Role in Woburn, MA Operations
Safecor Health, LLC, operating out of Woburn, Massachusetts, plays a crucial role as a repackaging firm within the pharmaceutical supply chain. Repackagers are vital for preparing medications, such as Haloperidol Lactate Injection (NDC: 67457-426-12), into formats suitable for specific institutional needs, often involving unit-dose packaging or the application of specialized tracking technologies like RFID tags. The current recall highlights a significant breakdown in their quality management system related to labeling accuracy. For procurement directors, this event underscores the inherent risks associated with outsourcing critical steps like labeling and serialization. While Safecor Health's facility in Woburn, MA, serves a specific niche, the error affecting 800 vials of Haloperidol Lactate demonstrates that even seemingly minor deviations can have substantial regulatory and patient safety implications. Supply chain VPs must ensure that their vendor qualification processes for repackaging partners are exceptionally robust, extending beyond basic quality audits to include detailed scrutiny of their labeling technology integration and error-proofing mechanisms. Business development executives should recognize that a strong, transparent quality system at every stage of the supply chain, including repackaging, is a non-negotiable requirement for maintaining market trust and avoiding costly recalls.
Supply Chain Vulnerability: Impact of RFID Mislabeling on Haloperidol Lactate Distribution
The recall of Haloperidol Lactate Injection, a critical antipsychotic medication, due to incorrect RFID tag labels by Safecor Health, LLC, exposes a significant vulnerability within the pharmaceutical supply chain, particularly concerning automated dispensing and inventory management systems. Haloperidol Lactate (UNII: 6387S86PK3) is widely used in hospital settings, where rapid and accurate identification is paramount. The application of incorrect serial numbers on KITCHECK RFID tags (e.g., 8001-03A3,00000000,003A-2560) can lead to a cascade of issues. For supply chain VPs, this means potential for misidentification of medication, leading to delayed or incorrect patient administration, inventory discrepancies, and non-compliance with track-and-trace regulations. Procurement teams must assess their exposure to products handled by Safecor Health or any repackager utilizing similar RFID technology, especially for high-alert medications. Regulatory affairs heads should evaluate their internal protocols for verifying third-party serialization and labeling data, as the integrity of these systems is crucial for preventing medication errors. The distribution of these 800 affected vials exclusively in Massachusetts means healthcare facilities in that state must be particularly vigilant in identifying and quarantining the specified lots (25381993 and 25391516) to safeguard patient care and maintain operational efficiency.
Mitigating Repackaging Risks: Strategic Sourcing and Enhanced Due Diligence
Given the Class II recall of Haloperidol Lactate Injection by Safecor Health, LLC, procurement directors must proactively address the risks associated with third-party repackaging. While specific alternative suppliers for Safecor Health are not immediately available in intelligence, the strategic imperative is clear: diversify repackaging partners or explore direct sourcing from primary manufacturers like Mylan Institutional LLC where feasible. Relying on a single repackager, especially for critical medications, introduces a single point of failure that can disrupt supply and compromise patient safety. Implementing rigorous qualification processes for all third-party logistics (3PL) and repackaging providers is non-negotiable. This includes comprehensive on-site audits, a thorough review of their quality management systems (QMS), and explicit verification of their serialization and labeling protocols, particularly for advanced technologies like RFID. Regulatory affairs heads must ensure that quality agreements with repackagers explicitly define responsibilities for RFID tagging accuracy, serial number management, and robust recall procedures. Business development executives should recognize that companies demonstrating superior compliance and quality control in their repackaging operations will gain a significant competitive advantage, attracting partners seeking to de-risk their supply chains and ensure uninterrupted access to essential medicines.
Regulatory Compliance Landscape: Proactive Risk Management for Repackaging Partners
The Class II recall initiated by Safecor Health, LLC, for Haloperidol Lactate Injection due to incorrect RFID tags, signals a significant lapse in quality control that demands attention from senior decision-makers. While specific prior regulatory actions against Safecor Health are not detailed in current intelligence, this event itself will trigger intensified scrutiny from the FDA. Regulatory affairs teams must closely monitor the FDA's ongoing assessment of this recall, as inadequate root cause analysis or ineffective corrective and preventive actions (CAPA) could escalate to further regulatory actions, including a Warning Letter or increased inspection frequency. For procurement and supply chain VPs, this incident serves as a critical reminder to review their own internal audit schedules and third-party oversight mechanisms. The industry has seen parallel events, such as Essential Wellness Pharma's Class II recall for sterility issues, reinforcing that regulatory vigilance is paramount across all supply chain partners. The FDA's 'Ongoing' status for this recall means Safecor Health is actively managing the situation, but the long-term impact on their reputation and future contracts will hinge entirely on their ability to demonstrate comprehensive remediation. Proactive risk management, including regular performance reviews and compliance checks of all repackaging partners, is essential to avoid similar disruptions and maintain supply chain integrity.
Remediation and Future Outlook: Navigating Post-Recall Scrutiny for Safecor Health
Safecor Health, LLC is now tasked with a comprehensive remediation effort following the Class II recall of Haloperidol Lactate Injection. The immediate priorities include identifying the precise root cause of the incorrect RFID tag application, implementing robust corrective and preventive actions (CAPA), and ensuring that all 800 affected 1mL vials from Lot 25381993 and 25391516 are accounted for and removed from distribution in Massachusetts. This process, initiated on October 10, 2025, and reported on December 10, 2025, is under active FDA oversight. For regulatory affairs teams, this means preparing for potential FDA follow-up inspections designed to verify the effectiveness of Safecor Health’s CAPA plan. Failure to adequately address the underlying issues could lead to an escalation of enforcement, potentially including a Warning Letter, which carries significant commercial and reputational consequences. Supply chain VPs should develop contingency plans for Haloperidol Lactate and any other products handled by Safecor Health, anticipating potential disruptions if the firm faces further regulatory challenges. Business development executives should recognize that a company's ability to swiftly and effectively manage a recall, demonstrating a commitment to quality and patient safety, is a key differentiator in securing future partnerships and maintaining market confidence. This event underscores the continuous need for vigilance and robust quality systems throughout the pharmaceutical supply chain.